Advanced in Chronic Obstructive Pulmonary Disease (COPD)

Dr. Mark L. Brantly

Pulmonary Medicine
1600 Sw Archer Rd, 
Gainesville, FL 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Advanced in Chronic Obstructive Pulmonary Disease (COPD)
1600 Sw Archer Rd, 
Gainesville, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Brantly is a Pulmonary Medicine provider in Gainesville, Florida. Dr. Brantly is rated as an Advanced provider by MediFind in the treatment of Chronic Obstructive Pulmonary Disease (COPD). His top areas of expertise are Emphysema, Alpha-1 Antitrypsin Deficiency (AATD), Subcutaneous Emphysema, Lymphangioleiomyomatosis, and Lung Transplant. Dr. Brantly is currently accepting new patients.

His clinical research consists of co-authoring 100 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 23 articles and participated in 2 clinical trials in the study of Chronic Obstructive Pulmonary Disease (COPD).

Specialties
Pulmonary Medicine
Licenses
Internal Medicine in FL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

1600 Sw Archer Rd, Gainesville, FL 32610

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

The Role of Conformational Diseases on Macrophage Function
The Role of Conformational Diseases on Macrophage Function
Enrollment Status: Recruiting
Publish Date: October 23, 2024
Intervention Type: Procedure, Drug
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
Enrollment Status: Recruiting
Publish Date: October 23, 2024
Intervention Type: Procedure
A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alpha1 Proteinase Inhibitor (Human) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency
A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alpha1 Proteinase Inhibitor (Human) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2025
Intervention Type: Biological, Other
Study Drug: Prolastin C
Study Phase: Phase 3
Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease - Alpha-1 Biomarker Research Consortium (A1BC)
Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease - Alpha-1 Biomarker Research Consortium (A1BC)
Enrollment Status: Active_not_recruiting
Publish Date: December 13, 2024
Phase 1/2 Study of Intravenous or Intrapleural Administration of a Serotype rh.10 Replication Deficient Adeno-associated Virus Gene Transfer Vector Expressing the Human Alpha-1 Antitrypsin cDNA to Individuals With Alpha-1 Antitrypsin Deficiency
Phase 1/2 Study of Intravenous or Intrapleural Administration of a Serotype rh.10 Replication Deficient Adeno-associated Virus Gene Transfer Vector Expressing the Human Alpha-1 Antitrypsin cDNA to Individuals With Alpha-1 Antitrypsin Deficiency
Enrollment Status: Completed
Publish Date: October 05, 2023
Intervention Type: Genetic
Study Phase: Phase 1/Phase 2
An Open-Label, Multicenter, Phase 1 Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Intravenous Doses of Inhibrx rhAAT-Fc (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency (AATD)
An Open-Label, Multicenter, Phase 1 Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Intravenous Doses of Inhibrx rhAAT-Fc (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency (AATD)
Enrollment Status: Completed
Publish Date: September 13, 2022
Intervention Type: Drug
Study Drug: INBRX-101/rhAAT-Fc
Study Phase: Phase 1
A Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-814 in PiZZ Subjects
A Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-814 in PiZZ Subjects
Enrollment Status: Terminated
Publish Date: February 02, 2022
Intervention Type: Drug
Study Phase: Phase 2
Phase I Safety Investigation of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency
Phase I Safety Investigation of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency
Enrollment Status: Completed
Publish Date: May 05, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1B/2A Study to Evaluate the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency
A Phase 1B/2A Study to Evaluate the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency
Enrollment Status: Completed
Publish Date: May 05, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 7 Less Clinical Trials

100 Total Publications

Pioglitazone Reduces Hepatic Alpha-1 Antitrypsin Accumulation Through Autophagy and AMPK Activation in Alpha-1 Antitrypsin Deficient Mice.
Pioglitazone Reduces Hepatic Alpha-1 Antitrypsin Accumulation Through Autophagy and AMPK Activation in Alpha-1 Antitrypsin Deficient Mice.
Journal: American journal of physiology. Gastrointestinal and liver physiology
Published: September 29, 2025
Similar Doctors
Distinguished in Chronic Obstructive Pulmonary Disease (COPD)
Dr. Joseph A. Tonner
Pulmonary Medicine
Distinguished in Chronic Obstructive Pulmonary Disease (COPD)
Dr. Joseph A. Tonner
Pulmonary Medicine
4343 W Newberry Rd Ste 6, 
Gainesville, FL 
 (4.6 miles away)
352-416-1082
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Joseph Tonner is a Pulmonary Medicine provider in Gainesville, Florida. Dr. Tonner is rated as a Distinguished provider by MediFind in the treatment of Chronic Obstructive Pulmonary Disease (COPD). His top areas of expertise are Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Lung Nodules, Asthma, and Advanced Bronchoscopy. Dr. Tonner is currently accepting new patients.

Distinguished in Chronic Obstructive Pulmonary Disease (COPD)
Dr. Perin Alfred
Pulmonary Medicine | Intensive Care Medicine | Sleep Medicine
Distinguished in Chronic Obstructive Pulmonary Disease (COPD)
Dr. Perin Alfred
Pulmonary Medicine | Intensive Care Medicine | Sleep Medicine
6041 Sw 73rd St Rd, 
Ocala, FL 
 (37.3 miles away)
352-629-1199
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Perin Alfred is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Ocala, Florida. Dr. Alfred is rated as a Distinguished provider by MediFind in the treatment of Chronic Obstructive Pulmonary Disease (COPD). His top areas of expertise are Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Hypersensitivity Pneumonitis, Idiopathic Pulmonary Fibrosis, and Advanced Bronchoscopy. Dr. Alfred is currently accepting new patients.

Distinguished in Chronic Obstructive Pulmonary Disease (COPD)
Dr. Anil K. Gogineni
Pulmonary Medicine | Intensive Care Medicine | Sleep Medicine
Distinguished in Chronic Obstructive Pulmonary Disease (COPD)
Dr. Anil K. Gogineni
Pulmonary Medicine | Intensive Care Medicine | Sleep Medicine

Ocala Lung And Critical Care Assocates Inc

1834 Sw 1st Ave, Suite 101, 
Ocala, FL 
 (34.8 miles away)
352-732-5552
Languages Spoken:
English, Hindi, Telugu
See accepted insurances
Accepting New Patients

Anil Gogineni is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Ocala, Florida. Dr. Gogineni is rated as a Distinguished provider by MediFind in the treatment of Chronic Obstructive Pulmonary Disease (COPD). His top areas of expertise are Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Pleural Effusion, Gastrostomy, and Advanced Bronchoscopy. Dr. Gogineni is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Brantly's expertise for a condition
ConditionClose
    View All 9 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile